Results of a phase 1 healthy volunteer (HV) study of the safety, tolerability, and pharmacokinetics of tovinontrine (IMR-687), an investigational, oral PDE9 inhibitor for the treatment of HFpEF

tovinontrine (IMR-687) - Imara, Inc

Jun 15, 2022